Who Supplies Rosuvastatin to India from IRELAND

To import finished pharmaceutical formulations containing Rosuvastatin into India, the Central Drugs Standard Control Organization (CDSCO) mandates that both the importer and the product be registered. The importer must obtain an Import License from the Directorate General of Foreign Trade (DGFT), and the product must be registered with CDSCO. The registration process involves submitting Form 40/41, which includes detailed information about the product, manufacturing process, and quality control measures. The timeline for obtaining import drug registration can vary but typically ranges from 6 to 12 months, depending on the completeness of the application and the regulatory review process. For Rosuvastatin formulations under HS Code 30049099, specific requirements include providing a Certificate of Pharmaceutical Product (CoPP), Good Manufacturing Practice (GMP) certificates, and stability data demonstrating compliance with Indian Pharmacopoeia standards. Additionally, a No Objection Certificate (NOC) from the Ministry of Health and Family Welfare may be required for certain formulations.

Imported pharmaceutical formulations containing Rosuvastatin must undergo quality testing at CDSCO-approved laboratories in India. Each batch requires a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, particularly for ICH Zone IV conditions, must be provided to ensure the product's efficacy and safety under Indian climatic conditions. Port inspection by customs drug inspectors is mandatory to verify the authenticity and quality of the imported products. If a batch fails quality testing, it may be rejected, and the importer could face penalties or be barred from future imports.

Between 2024 and 2026, CDSCO has implemented stricter regulations for importing pharmaceutical products, including Rosuvastatin formulations. The introduction of the Production Linked Incentive (PLI) scheme has incentivized domestic manufacturing, leading to a reduction in import dependency. Bilateral agreements between India and Ireland have facilitated smoother trade relations, with mutual recognition of Good Manufacturing Practices (GMP) and streamlined import procedures. These developments aim to enhance the quality and availability of pharmaceutical products in India while promoting self-reliance.

India imports finished Rosuvastatin formulations to meet the demand for patented and branded products not manufactured domestically. Specific dosage forms, such as extended-release tablets, may not be produced locally, necessitating imports. Despite a robust domestic pharmaceutical industry, certain formulations are still imported to fulfill market needs. The market size for Rosuvastatin in India is substantial, with a growing number of patients requiring cholesterol-lowering medications.

The Basic Customs Duty (BCD) for finished pharmaceutical formulations under HS Code 30049099 is 10%. An Integrated Goods and Services Tax (IGST) of 12% is applicable on the imported value. Additionally, a Social Welfare Surcharge (SWS) of 10% on BCD is levied. There are no specific exemptions or concessional duties for imports from Ireland. The total landed duty, combining BCD, SWS, and IGST, is approximately 17.10%.

India sources finished Rosuvastatin formulations from Ireland due to the country's strong pharmaceutical manufacturing capabilities, adherence to international quality standards, and the availability of specialized dosage forms not produced domestically. Ireland's pharmaceutical industry is known for its innovation and compliance with Good Manufacturing Practices (GMP), making it a reliable supplier. Other suppliers, such as China, Germany, and the United States, also export Rosuvastatin formulations to India, but Ireland's competitive advantage lies in its quality assurance and specialized product offerings.

India imports finished Rosuvastatin formulations from Ireland due to the availability of patented formulations and specialized dosage forms not produced domestically. Ireland's pharmaceutical industry offers high-quality products that meet international standards, ensuring efficacy and safety. Specific formulations, such as extended-release tablets, are sourced from Ireland to fulfill market demand.

Compared to other origins like China, Germany, and the United States, Ireland offers a competitive advantage in terms of product quality, regulatory compliance, and specialized formulations. While China may offer lower prices, concerns about quality and regulatory standards may arise. Germany and the United States provide high-quality products but may have higher costs and longer lead times. Ireland's unique advantage lies in its balance of quality, compliance, and cost-effectiveness.

Potential risks for Indian importers include single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. To mitigate these risks, importers should diversify their supplier base, monitor currency trends, stay updated on regulatory changes, conduct regular quality audits, and maintain buffer stock to manage supply chain disruptions.

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source.
2. 2Inventory Planning: Maintain adequate stock levels to buffer against supply chain disruptions.
3. 3Payment Terms: Negotiate favorable payment terms, such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP).
4. 4Supplier Qualification: Conduct thorough due diligence on suppliers, including audits and compliance checks.
5. 5Regulatory Compliance: Stay informed about regulatory changes and ensure all imports meet CDSCO requirements.

1. 1DGFT Import License: Obtain an Importer Exporter Code (IEC) from the Directorate General of Foreign Trade.
2. 2CDSCO Registration: Register the product with CDSCO by submitting Form 40/41.
3. 3Drug Import License: Apply for a Drug Import License from CDSCO.
4. 4No Objection Certificate (NOC): Obtain an NOC from the Ministry of Health and Family Welfare, if required.